In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit.
https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?fbclid=IwAR0Mb_aEMtGAVQRzBtwVC3oDyhfI2pSLQlrBQ3MyD6ub4cD-XyqBdN7dpgg